Bushen Kaixuan Tongluo fòmil amelyore maladi ren dyabetik nan sourit Db/db atravè aktivasyon chemen CAMP/PKA/CREB-Bcl-2 ak amelyorasyon metabolis glikoz-lipid.
Oct 15, 2025
3 Rezilta
3.1 Efè fòmil Bushen Kaixuan Tongluo sou kondisyon jeneral sourit db/db
Sourit nan gwoup vid la te aktif ak fouri briyan. Sourit yo nan gwoup modèl la te obèz, endispansab, epi yo te montre tan aktivite siyifikativman redwi. Sourit nan tout gwoup medikaman yo te montre sèten amelyorasyon konpare ak gwoup modèl la.

TCM ZÈB CISTANCHE EXTRÈ POU SANTE REN
3.2 Efè fòmil Bushen Kaixuan Tongluo sou pwa kò sourit db/db
Pandan peryòd eksperimantal la, konpare ak gwoup vid la, pwa kò nan gwoup modèl la ogmante anpil (P<0.01). Compared with the model group, body weight in all medication groups tended to decrease, with differences appearing from week 8; the high-dose Bushen Kaixuan Tongluo Formula group showed the best effect. See Table 2.
Tablo 2. Efè fòmil ki baze sou Cistanche sou pwa kò nan sourit db/db (x̄±s, n=6)
| Gwoup | Dòz (g·kg⁻¹) | Semèn 0 (g) | Semèn 4 (g) | Semèn 8 (g) | Semèn 12 (g) |
|---|---|---|---|---|---|
| Vid | - | 24.38 ± 0.35 | 29.88 ± 0.46 | 32.92 ± 0.90 | 33.14 ± 0.49 |
| Modèl | - | 37.27 ± 1.46 | 45.63 ± 1.85¹ | 49.38 ± 3.52² | 50.86 ± 4.69² |
| Fòmil ki ba-dòz | 7 | 36.47 ± 1.40 | 44.07 ± 1.84 | 43.41 ± 3.11 | 40.03 ± 1.36³ |
| Fòmil dòz mwayen | 14 | 37.57 ± 1.01 | 44.23 ± 2.05 | 42.47 ± 3.36³ | 40.25 ± 4.78³ |
| Fòmil ki gen gwo dòz | 28 | 38.03 ± 1.62 | 43.28 ± 1.63 | 40.82 ± 1.87⁴ | 36.49 ± 1.32⁴ |
| Irbesartan | 0.02 | 38.58 ± 1.66 | 44.63 ± 1.66 | 46.03 ± 2.10 | 44.83 ± 2.43 |
3.3 Efè fòmil Bushen Kaixuan Tongluo sou fonksyon ren sourit db/db
Konpare ak gwoup vid la, Scr nan gwoup modèl la te montre yon tandans anlè san siyifikasyon estatistik, pandan y ap BUN, uALB, ak nivo ACR yo te siyifikativman elve (P<0.05). Compared with the model group, Scr in the formula groups tended to decrease without statistical significance; BUN, uALB, and ACR were significantly reduced (P<0.05), with the medium-dose formula group showing the best effect. In the irbesartan group, Scr and BUN tended to decrease without statistical significance, while uALB and ACR decreased significantly (P<0.01). See Table 3.
Tablo 3. Efè fòmil ki baze sou Cistanche sou fonksyon ren nan sourit db/db (x̄±s, n=6)
| Gwoup | Dòz (g·kg⁻¹) | Scr (μmol/L) | BUN (mmol/L) | uALB (mg/L) | ACR (mg/g) |
|---|---|---|---|---|---|
| Vid | - | 53.76 ± 0.91 | 6.79 ± 0.26 | 1.69 ± 0.13 | 9.54 ± 1.01 |
| Modèl | - | 61.34 ± 1.89 | 9.08 ± 0.73¹ | 4.16 ± 0.19² | 63.08 ± 9.92² |
| Fòmil ki ba-dòz | 7 | 55.69 ± 3.55 | 6.99 ± 0.54³ | 1.81 ± 0.05⁴ | 21.37 ± 0.62⁴ |
| Fòmil dòz mwayen | 14 | 50.45 ± 3.02 | 6.48 ± 0.26⁴ | 1.21 ± 0.08⁴ | 19.99 ± 2.03⁴ |
| Fòmil ki gen gwo dòz | 28 | 51.59 ± 3.09 | 6.01 ± 0.30⁴ | 1.34 ± 0.09⁴ | 22.72 ± 1.38⁴ |
| Irbesartan | 0.02 | 55.33 ± 2.31 | 7.93 ± 0.48 | 1.37 ± 0.09⁴ | 27.00 ± 3.83⁴ |
3.4 Efè fòmil Bushen Kaixuan Tongluo sou fonksyon fwa ak metabolis lipid sourit db/db
Konpare ak gwoup vid la, nivo ALT, AST, TC, ak TG nan gwoup modèl la ogmante anpil (P<0.05). Compared with the model group, AST and ALT in the formula groups showed downward trends without statistical significance, TC decreased significantly (P<0.01), TG in the medium-dose formula group decreased significantly (P<0.05), and other TCM groups showed a downward trend in TG without statistical significance. In the irbesartan group, TC showed a downward trend without statistical significance, while TG decreased significantly (P<0.01). See Table 4.

Tablo 4. Efè fòmil ki baze sou Cistanche sou fonksyon fwa ak metabolis lipid (x̄±s, n=6)
| Gwoup | Dòz (g·kg⁻¹) | AST (U/L) | ALT (U/L) | TC (mmol/L) | TG (mmol/L) |
|---|---|---|---|---|---|
| Vid | - | 158.80 ± 6.44 | 56.31 ± 3.00 | 2.40 ± 0.08 | 1.22 ± 0.11 |
| Modèl | - | 310.20 ± 53.31¹ | 206.70 ± 24.98² | 2.98 ± 0.21¹ | 3.71 ± 0.22² |
| Fòmil ki ba-dòz | 7 | 202.50 ± 22.27 | 125.30 ± 8.74 | 2.09 ± 0.06⁴ | 3.13 ± 0.18 |
| Fòmil dòz mwayen | 14 | 263.10 ± 31.37 | 166.80 ± 34.28 | 1.94 ± 0.10⁴ | 2.23 ± 0.32⁴ |
| Fòmil ki gen gwo dòz | 28 | 266.20 ± 22.96 | 166.80 ± 22.61 | 1.97 ± 0.05⁴ | 2.96 ± 0.26 |
| Irbesartan | 0.02 | 215.30 ± 14.43 | 101.70 ± 20.41² | 2.50 ± 0.19 | 2.42 ± 0.31⁴ |
3.5 Efè fòmil Bushen Kaixuan Tongluo sou metabolis glikoz sourit db/db
Konpare ak gwoup vid la, nivo FBG, LEP, GSP, ak INS yo te ogmante anpil nan gwoup modèl la (P<0.05). Compared with the model group, FBG in the medication groups showed no downward trend; LEP in the formula groups tended to decrease without statistical significance, while LEP in the irbesartan group decreased significantly (P<0.05). GSP and INS decreased significantly in all medication groups (P<0.05), with the high-dose formula group showing the best effect. See Table 5.
Tablo 5. Efè fòmil ki baze sou Cistanche sou metabolis glikoz nan sourit db/db (x̄±s, n=6)
| Gwoup | Dòz (g·kg⁻¹) | FBG (mmol/L) | LEP (ng/mL) | GSP (μmol/L) | INS (μIU/mL) |
|---|---|---|---|---|---|
| Vid | - | 4.17 ± 0.26 | 5.32 ± 0.18 | 127.30 ± 2.69 | 7.99 ± 0.13 |
| Modèl | - | 18.87 ± 3.84² | 6.46 ± 0.22¹ | 239.40 ± 14.98² | 23.34 ± 2.16² |
| Fòmil ki ba-dòz | 7 | 28.22 ± 2.30 | 5.60 ± 0.30 | 201.80 ± 4.68⁴ | 18.52 ± 0.72³ |
| Fòmil dòz mwayen | 14 | 28.00 ± 3.33 | 5.98 ± 0.46 | 193.30 ± 5.79⁴ | 15.64 ± 0.33⁴ |
| Fòmil ki gen gwo dòz | 28 | 33.30 ± 0.00⁴ | 5.50 ± 0.08 | 178.70 ± 2.63⁴ | 14.57 ± 0.23⁴ |
| Irbesartan | 0.02 | 25.62 ± 2.36 | 5.27 ± 0.14³ | 163.80 ± 2.32⁴ | 14.28 ± 0.57⁴ |
3.6 Efè fòmil Bushen Kaixuan Tongluo sou istopatoloji ren sourit db/db
Tach HE te montre nòmal estrikti ren nan gwoup la vid: glomeruli regilye ak selil epitelyal tubulaires entak. Gwoup modèl la te montre mòfoloji glomerulè iregilye, pwopagasyon selil mesangyal modere, enfiltrasyon selil enflamatwa, ak koripsyon vakuolè nan selil epitelyal tubulaires. Chanjman patolojik sa yo te soulaje nan diferan degre nan gwoup fòmil ki ba, mwayen, ak gwo dòz ak gwoup irbesartan. (Imaj konvèti an rezime tèks.)
Tach PAS te montre yon ti kantite depo matris ekstraselilè (ECM) nan glomeruli nan gwoup la vid, pandan y ap gwoup la modèl ekspoze masiv depo ECM ak manbràn sousòl ansibleman epè. Karakteristik patolojik sa yo te amelyore nan yon sèten mezi nan tout twa gwoup dòz fòmil la ak nan gwoup irbesartan. (Imaj konvèti an rezime tèks.)
Masson tach te montre nòmal estrikti glomerular ak minimòm depozisyon kolagen an patolojik nan gwoup la vid. Gwoup modèl la te montre anpil depo fib kolagen an ble nan glomeruli ak entèstisyòm. Gwoup dòz fòmil yo ak gwoup irbesartan yo te montre amelyorasyon nan diferan degre. (Imaj konvèti an rezime tèks.)
3.7 Efè fòmil Bushen Kaixuan Tongluo sou ekspresyon p-PKA ak p-CREB nan tisi ren sourit db/db
Konpare ak gwoup vid la, entansite tach nan p-PKA ak p-CREB nan tisi ren nan gwoup modèl la te siyifikativman redwi (P<0.01). Compared with the model group, p-PKA expression in the medium-dose formula group increased significantly (P<0.01), and p-CREB showed an upward trend without statistical significance. See Figure 4 and Table 6. (Image converted to text summary.)

3.8 Efè fòmil Bushen Kaixuan Tongluo sou ekspresyon pwoteyin p-PKA, PKA, p-CREB, CREB, ak Bcl-2 nan tisi ren sourit db/db
Konpare ak gwoup vid la, rapò ekspresyon pwoteyin p-PKA/PKA ak p-CREB/CREB, osi byen ke nivo Bcl-2, yo te siyifikativman diminye nan gwoup modèl la (P<0.05). Compared with the model group, these indices were significantly increased in the medium-dose formula group (P<0.01). See Figure 5 and Table 7. (Image converted to text summary.)
3.9 Efè fòmil Bushen Kaixuan Tongluo sou ekspresyon mRNA PKA, CREB, ak Bcl-2 nan tisi ren sourit db/db
Konpare ak gwoup vid la, ekspresyon mRNA nan PKA, CREB, ak Bcl-2 te siyifikativman diminye nan gwoup modèl la (P<0.01). Compared with the model group, mRNA expression of PKA, CREB, and Bcl-2 was significantly increased in the medium-dose formula group (P<0.05). See Table 8.
Kontèks mekanik ak ekstrè diskisyon
CAMP siyal se yon sant santral pou metabolis enèji ak règleman jèn, enpòtan anpil pou omeyostazi ren. Adenylate cyclase (AC) jenere cAMP, ki alosterikman aktive PKA. Aktive PKA fosforil CREB pou fòme p-CREB, ki transloke nan nwayo a, mare eleman repons cAMP (CRE) nan pwomotè sib yo, epi li kòmanse transkripsyon efektè en tankou Bcl-2 pou egzèse efè anti-apoptotik ak bese blesi selilè.
Nan DKD, ipèglisemi kwonik siprime aktivite AC ak amelyore fosfodiesteraz (PDE) degradasyon, diminye nivo cAMP, febli PKA/CREB siyal, febli fonksyon mitokondriyo, sentèz antioksidan, ak ekspresyon faktè anti-apoptotik, kidonk akselere glomerulosclerosis ak fibroz tubulointerstitial.
Aktive siyal cAMP/PKA ede kenbe pwoteyin dyafram podocyte fant, pwoteje baryè filtraj la, diminye proteinuria, pwovoke jèn antioksidan (egzanp, SOD2), ak elve Bcl-2 pou anpeche akimilasyon ROS ak pwoteje selil yo nan kondisyon ki gen glikoz.
Nòmalize glikoz nan san ak amelyore pwofil lipid yo ka diminye akimilasyon AGEs, diminye epesman GBM ak blesi podosit, epi siprime depozisyon lipid ren ak enfiltrasyon makrofaj, finalman retade sklewoz ak fibwoz.
Nan etid sa a, fòmil la amelyore kondisyon jeneral, siyifikativman amelyore fonksyon ren, ak korije maladi metabolis glikoz-lipid nan sourit db/db. Istopatoloji te montre soulajman GBM epesman, ekspansyon mezanjyal, ak depozisyon kolagen an entèrstisyèl. Mekanistikman, fòmil la regilasyon ren PKA, CREB, ak Bcl-2 mRNA ak ogmante p-PKA/PKA, p-CREB/CREB, ak Bcl-2 nivo pwoteyin, aktive nœuds debaz nan chemen cAMP la, amelyore kapasite antioksidatif, ak amelyore fonksyon baryè filtraj.
Konklizyon: Bushen Kaixuan Tongluo Fòmil amelyore fonksyon epatik ak ren, korije twoub metabolis lipid ak glikoz, epi diminye fibwoz ren ak estrès oksidatif atravè regilasyon nan chemen cAMP, kidonk konfere renoprotection. Pandan ke prèv milti-nivo sipòte patisipasyon chemen cAMP, efèktè en tankou BDNF pa te egzamine epi yo jistifye envestigasyon nan lavni.
Konfli enterè
Pa gen konfli enterè.
Referans
[1] Yang R, Chen R, Xu N, et al. Vize terapetik nan PRSS3 pou soulaje domaj ren nan DKD. Selil Biol Toxicol. 2025;41(1):108.
[2] Wang Y, Gu S, Xie Z, et al. Tandans ak disparisyon nan chay maladi ren kwonik akòz dyabèt tip 2 nan peyi Lachin Soti 1990 rive 2021: yon etid ki baze sou popilasyon an. J Dyabèt. 2025;17(4):e70084.
[3] 徐淼, 贾晓蕾, 秦灵灵, 等. 基于PI3K/Akt信号通路探讨中医药干预糖尿病肾病的研究进展. 中国实验方剂学杂志. 2025;31(11):90-97. Sitasyon angle: Xu M, Jia XL, Qin LL, et al. Pwogrè rechèch sou chemen siyal PI3K/Akt nan prevansyon ak tretman nefropati dyabetik ak entèvansyon medikaman tradisyonèl Chinwa. Chin J Exp Tradit Med Form. 2025;31(11):90-97.
[4] 张钦媛, 陈彦旭, 秦大凯, 等. 中药调控Nrf2信号通路干预糖尿病肾病研究进展. 中国实验方剂学杂志. 2025;31(18):277-285. Sitasyon angle: Zhang QY, Chen YX, Qin DK, et al. Entèvansyon nan Medsin Tradisyonèl Chinwa nan Nefropati dyabetik pa reglemante chemen siyal Nrf2: yon revizyon. Chin J Exp Tradit Med Form. 2025;31(18):277-285.
[5] Zhang Y, Yang Y, Hu X, et al. RAS protein activator-like 2 (RASAL2) inisye rarifikasyon kapilè peritubular nan fibwoz entèrstisyèl ren ipoksik. Transl Res. 2024;269:14-30.
[6] Wang H, Shi H, Sheng G, et al. Kontinyòm chimik-farmakolojik nan fòmil Yucan: korelasyon ekspoze eleman-tisi entegre enfòme rezo sib maladi ren dyabetik. J Chromatogr B Analyt Technol Biomed Life Sci. 2025:124715.
[7] 王婷, 黄莉吉, 余江毅. "治未病"指导下的糖尿病肾病防治策略. 江西中医药. 2022;53(04):12-15. Sitasyon angle: Wang T, Huang LJ, Yu JY. Estrateji Prevansyon ak Tretman nan Nefropati dyabetik anba Pedagojik la nan "Tretman Prevantif nan Maladi". Jiangxi J Tradit Chin Med. 2022;53(04):12-15.
[8] 周洛卿, 王友, 贾晓蕾, 等. 补肾开玄通络方联合西药治疗G3a期糖尿病肾病的疗效观察. 北京中医药. 2024;43(05):551-554.






